Seattle's Juno Therapeutics managed to top the already superlative expectations for its Wall Street debut, grossing about $264.6 million and pulling off the Nasdaq's biggest 2014 biotech IPO in the waning days of a huge year.
To help think through the vagaries of biotech valuations, FierceBiotech has invited a stellar panel of biotech financiers, with deep experience investing in and working with public as well as private biotechs, to speak at a breakfast event on Tuesday, Jan. 13, during the annual J.P. Morgan Healthcare Conference.
A few things struck us while gathering this year's class of the Fierce 15, our 12th annual take on some of the most noteworthy private biotech upstarts making headway these days. First, you'll find a higher than usual accumulation of early-stage companies in the group. And it's not hard to see why. Once the IPO window opened in early 2013, we saw a whole slew of earlier winners jump through--many like bluebird and Agios winning some extraordinary returns for investors. By the end of last year we were beginning to see plenty of other newcomers make the move as well, definitely winnowing out the number of more advanced companies to select from.
Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no guarantee of success, particularly in this increasingly challenging market. At the same time, though, it was no great feat to find 15 women who have been doing some amazing things. Check out the special report >>
POPULAR COMMENT THREADS
Welcome to the latest edition of our weekly EuroBiotech Report.
AbbVie won an expected FDA approval for its next-generation treatment for hepatitis C, kicking off a race with Gilead Sciences for dominance in a blockbuster field.
Despite loud objections from its advisers, the FDA granted an accelerated approval to AstraZeneca's ovarian cancer treatment, clearing an oral therapy the U.K. drugmaker believes will bring in blockbuster sales.
Gilead Sciences is pushing further into oncology R&D, teaming up with Ono Pharmaceutical on a cancer treatment that could complement its first major success in the field.
Eli Lilly is buying back into Adocia's pitch for a fast-acting insulin, reversing an earlier decision and signing a collaboration deal worth up to $570 million.
Yet another big Phase III test of an experimental Alzheimer's drug has flopped. And this time it's Roche's turn to admit defeat.
From Our Sister Sites
Myriad Genetics won FDA approval for its companion diagnostic test for AstraZeneca's ovarian cancer drug Lynparza, giving the company a boost as it recoups from its latest patent battle loss and helping it gain ground in a fast-growing market.
Just one month after announcing a $66 billion pact to buy Allergan, Actavis is eyeing Spain's Almirall as a way to boost its European growth, according to Bloomberg.